LabEx MAbImprove
FR
EN
Intranet
Contact us
Rechercher
OK
Ouvrir ou fermer la navigation
Home
The LabEx
Who we are?
Teams/Research groups
Platforms
Governance
Industrial workshops
Past events
Research
Presentation
KQ1 – How can target activity be modulated through antibody binding?
KQ2 – How can antibody activity be optimised by adjusting format?
KQ3 – How can antibody efficacy be increased using combinations?
KQ4 – How can antibody administration be improved?
CDI1 – Interdisciplinary innovation
CDI2 – Bio-clinical interface
Training
MAbInnovation
MAbBoost
Licensing
Health
Teaching tools
Clinical
Socioeconomic
Nomenclature
News
FR
EN
Intranet
Contact us
News
Home
>
News
>
Research
>
First-in-human phase I study for SurgiMab’s molecule SGM-101 launched in Montpellier Cancer Institute.
First-in-human phase I study for SurgiMab’s molecule SGM-101 launched in Montpellier Cancer Institute.
Research •
20/05/2015
